Murlentamab
Modify Date: 2024-04-07 06:46:57
Murlentamab structure
|
Common Name | Murlentamab | ||
|---|---|---|---|---|
| CAS Number | 2058047-65-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MurlentamabMurlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming[1]. |
| Name | Murlentamab |
|---|
| Description | Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming[1]. |
|---|---|
| Related Catalog | |
| Target |
AMHRII[1] |
| In Vivo | Murlentamab (20 mg/kg；静脉注射；每周两次，持续 4 周) 在体内抑制小鼠肝癌 PDX 模型中的肿瘤生长[2]。 |
| References |
| No Any Chemical & Physical Properties |